Recent DARPA research has demonstrated the ability to accelerate production of millions of doses of vaccine using novel plant-based methods. But clinical trials for vaccines, drugs or other biologics can’t be initiated without preclinical evidence of their safety in humans. To create a pathway for fielding safe and effective countermeasures, DARPA has launched the Microphysiological Systems program. MPS will develop a platform that uses engineered human tissue to mimic human physiological systems. DARPA graphic